Aspirin in patients with coronary artery disease: Is it simply irresistible?

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 2, 2001, Pages 117-126

  Nair, Girish V ^a   Davis, Christopher J ^a   McKenzie, Marcus E ^a   Lowry, David R ^a   Serebruany, Victor L ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; IFETROBAN; INDOBUFEN; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RIDOGREL; SIBRAFIBAN; SULFINPYRAZONE; SULOTROBAN; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; TRIFLUSAL; VAPIPROST;

ABDOMINAL PAIN; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INFORMATION; DRUG MECHANISM; DRUG USE; ENTERIC COATED TABLET; HEARTBURN; HEMATOCHEZIA; HUMAN; MORBIDITY; MORTALITY; NAUSEA; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ASPIRIN; BENZAMIDINES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CORONARY DISEASE; CYCLOOXYGENASE INHIBITORS; DIABETES COMPLICATIONS; DIPYRIDAMOLE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; OXIMES; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; THROMBOSIS; THROMBOXANE-A SYNTHASE; TICLOPIDINE; VASODILATOR AGENTS;

EID: 0034925548     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011220615447     Document Type: Review

References (121)

1. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
2. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
3. International, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina
4. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
6. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
7. Coronary arteriographic findings soon after non-Q-wave myocardial infarction
8. Clinicopathologic correlates of acute ischemic heart disease syndromes
9. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion
10. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
11. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration cooperative study
12. Aspirin, sulfinprazone, or both in unstable angina: Results of a Canadian multicenter trial
13. Aspirin, heparin, or both to treat acute unstable angina
14. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
15. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction
16. Aspirin in coronary heart disease
17. Secondary prevention of myocardial infarction: A comparison of acetylsalicylic acid, placebo and pheprocoumon
18. Aspirin and secondary mortality after myocardial infarction
19. Persantine and aspirin in coronary heart disease
20. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction
21. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
22. Salicylates and bleeding: The aspirin tolerance test
23. Lipid-derived autacoids: Eicanosoids and platelet-activating factor
24. Prostaglandin endoperoxide synthases-1 and-2
25. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
26. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity
27. The endothelium: Modulator of vascular smooth muscle tone
28. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
29. Modulation of coronary vasomotor tone in humans: Progressive endothelial dysfunction with different early stages of coronary atherosclerosis
30. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions
31. Effects of age on endothelium-dependent vasodilation of resistance coronary arteries by acetylcholine in humans
32. Effects of high density lipoprotein on acetylcholine-induced coronary vasoactivity
33. Heterogeneity of vasomotor response to acetylcholine along the human coronary artery
34. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure: Role of endothelium-derived vasodilating and vasoconstricting factors
35. Elevated glucose promotes generation of endothelium-dependent relaxations by activating protein kinase C
36. Aspirin improves endothelial dysfunction in atherosclerosis
37. Metabolism of thromboxane B2 in man
38. Identification of 11-dehydro-TXB2, as a suitable parameter for monitoring thromboxane production in the human
39. Radioimmunoassay for 11-dehydro-TXB2. A method for monitoring thromboxane production in vivo
40. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine
41. Metabolism of prostacyclin and 6 keto-prostaglandin F1 alpha in man
42. Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side effects
43. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man
44. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa
45. Aspirin-induced gastric mucosa damage: Prevention by enteric-coating and relation to prostaglandin synthesis
46. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin
47. Differences in inhibition of PGIL2 production by aspirin in rabbit artery and vein segments
48. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects
49. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin
50. Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane productin in patients with atherosclerosis
51. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in vivo
52. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin
53. Selective cumulative inhibition of platelet thromboxane production by low dose aspirin in healthy subjects
54. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin
55. Enhanced platelet accumulation onto injured carotid arteries in rabbits following aspirin treatment
56. The effect of aspirin and salicylate on platelet/vessel wall interactions in rabbits
57. Effect of platelet-modifying drugs on arterial thromboembolism in baboons: Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition
58. Aspirin inhibits platelet function independent of the acetylation of cyclooxygenase
59. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition
60. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation
61. Aspirin acetylates fibrinogen and enhances fibrinolysis: Fibrinolytic effect is independent of changes in plasminogen activator levels
62. Increased blood fibrinolytic activity after aspirin ingestion
63. Influence of acetylsalicylic acid and salicylamide on the coagulation of blood
64. Measurement of thrombin generation in whole blood: The effect of heparin and aspirin
65. Antiplatelet drugs and generation of thrombin in clotting blood
66. Platelet activation mechanisms and markers in arterial thrombosis
67. Prostacyclin and atherosclerosis
68. Thromboxane A2 biosynthesis in human disease
69. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina
70. The stimulation of arachidonic acid metabolism in human platelets by hydrodynamic forces
71. Shear-induced platelet aggregation can be mediated by VWF released from platelets, as well as by exogenous large or unusually large VWF-multimers, requires adenosine diphosphate, and is resistant to aspirin
72. Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries
73. Norepinepherine-induced human platelet activation in vivo is only partly counteracted by aspirin
74. Incomplete inhibition of platelet secretion by low-dose aspirin
75. Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease
76. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy
77. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers
78. Development of aspirin resistance in persons with previous ischemic stroke
79. Antiplatelet drugs
80. Dipyridamole
81. Second European Stroke Prevention Study: Antiplatelet therapy is effective regardless of age. ESPS2 Working Group
82. Aggrenox: A combination of antiplatelet drugs for stroke prevention
83. The biochemical pharmacology of thromboxane synthase inhibition in man
84. Synthesis of prostacyclin from platelet derived endoperoxides by cultured human endothelial cells
85. Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs
86. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade
87. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)
88. Prevention of ischaemic cardiac events in unstable angina and non-Q infarction. PRINCE, a placebo controlled trial with Ifegatran-thromboxane A2 receptor antagonist
89. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism
90. Prostaglandin endoperoxidases modulate the response to thromboxane synthase inhibition during coronary thrombosis
91. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study
92. Changing from intensive anticoagulation to treatment with aspirin alone for coronary stents: The experience of one center in the United Kingdom
93. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
94. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting
95. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: The Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) Study
96. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients with Multicenter Aspirin and Ticlopidine Trial After Intracoronary Stenting (MATTIS)
97. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
98. Pharmacology of ticlopidine: A review
99. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients
100. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel
101. Clopidogrel versus ticlopidine after intracoronary stent placement
102. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
103. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
104. Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting
105. Thrombotic thrombocytopenic purpura associated with clopidogrel
106. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
107. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
108. Randomized placebo-controlled trials of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
109. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
110. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
111. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
112. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
113. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial
114. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events
115. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
116. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy
117. Abciximab reduces mortality in diabetics following percutaneous coronary intervention